Evotec SE

XTRA:EVT 株式レポート

時価総額：€895.0m

Evotec 将来の成長

Future 基準チェック /36

Evotec利益と収益がそれぞれ年間72.7%と6.6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に7.3% 75.9%なると予測されています。

主要情報

72.7%

収益成長率

75.87%

EPS成長率

Life Sciences 収益成長20.2%
収益成長率6.6%
将来の株主資本利益率7.26%
アナリストカバレッジ

Good

最終更新日11 May 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • May 23

EVT: Future Milestone And Royalty Stream Will Support Earnings Upside

Analysts have trimmed their price target on Evotec from €10.40 to €10.00, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E that now sit slightly below prior estimates but remain within a similar range. What's in the News Evotec and Almirall nominated a small molecule preclinical development candidate for immune mediated inflammatory skin diseases, using Evotec’s AI/ML supported discovery and preclinical platforms, with potential success based milestones of up to €230 million per program plus high single digit royalties on net sales (Key Developments).
ナラティブの更新 • May 04

EVT: Activist Proposals And 2026 Guidance Will Drive Future Upside

Analysts have slightly reduced their price target on Evotec to €6.83 from €6.92, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News Evotec expects full year 2026 group revenues of approximately €700 million to €780 million, with constant currency guidance of €730 million to €810 million (company guidance).
ナラティブの更新 • Apr 19

EVT: Higher Revenue Guidance Will Be Undermined By Weaker Profitability Assumptions

Analysts have adjusted their price target on Evotec to €4.40. The change is framed by updated views on discount rates, revenue growth assumptions, profit margins and a higher future P/E multiple.
ナラティブの更新 • Apr 05

EVT: 2025 And 2026 Revenue Guidance Will Support Future Upside

Analysts have reduced their price target on Evotec by €1.80, citing updated views on fair value, discount rate, revenue growth and profit margin assumptions, and also reflecting a revised future P/E outlook. What's in the News Evotec issued new earnings guidance for full-year 2026, targeting group revenues of about €700-780 million or €730-810 million at constant exchange rates (Key Developments).
ナラティブの更新 • Mar 21

EVT: Earnings Outlook Will Balance Higher Guidance With Tighter Profit Assumptions

Analysts have reduced their Evotec price targets from €6.00 to €4.40 as they apply a higher discount rate, assume slower revenue growth and lower profit margins, and factor in a slightly higher future P/E of 24.33x. What's in the News Evotec raised its full-year 2025 earnings guidance, now expecting group revenues of approximately €788 million at the high end of its €760 to €800 million range, or €811 million at constant exchange rates (Key Developments) The company confirmed new earnings guidance for full-year 2026, with group revenues expected in a range of approximately €700 to €780 million, or €730 to €810 million at constant exchange rates (Key Developments) Valuation Changes Fair Value: reduced from €6.00 to €4.40 per share, reflecting a lower implied valuation level.
ナラティブの更新 • Mar 07

EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside

Analysts have trimmed their price target on Evotec to €10.40. This reflects updated assumptions for revenue growth, profit margins and a higher future P/E multiple.
ナラティブの更新 • Feb 20

EVT: Kidney Disease Milestone Prospects Will Support Future Upside

Analysts have made only a very small adjustment to their Evotec price target, keeping it effectively unchanged at about €8.72. Updated assumptions for discount rate, revenue growth, profit margin and future P/E remain closely aligned with prior estimates.
ナラティブの更新 • Feb 06

EVT: Kidney Disease Milestones And Novo Stake Sale Will Support Future Upside

Analysts have adjusted their fair value estimate for Evotec from €8.46 to approximately €8.72, citing updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the main factors behind the latest price target revision. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, equal to about 5% of Evotec's share capital, after previously holding 14.9 million shares or 8.4% of the company (Key Developments).
ナラティブの更新 • Jan 22

EVT: Milestone Progress And Share Buybacks Will Support Future Upside

Analysts have slightly adjusted their price target on Evotec to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. The fair value estimate remains steady at €8.46.
ナラティブの更新 • Jan 07

EVT: Milestone Payment And Buyback Will Support Future Upside

Analysts have kept their fair value estimate for Evotec steady at €8.46, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, reflecting a largely unchanged fundamental view. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, around 5% of the company, after previously holding 14.9 million shares or 8.4% of the capital.
ナラティブの更新 • Dec 17

EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside

Analysts have trimmed their price target on Evotec from €12.00 to €10.40. The revision reflects a higher perceived discount rate despite stronger expectations for revenue growth and profit margins.
ナラティブの更新 • Dec 03

EVT: Share Buybacks And Milestone Payment Will Support Future Upside

Analysts have lowered their price target on Evotec from approximately $9.47 to about $8.46. They cited a higher perceived discount rate and slightly softer long term revenue growth expectations, partially offset by improved profit margin forecasts and a more moderate future price to earnings multiple.
ナラティブの更新 • Aug 21

Large Pharma Partnerships And AI Platforms Will Open New Markets

The notable reduction in Evotec’s Analyst Price Target reflects a lower expected future P/E and a slight moderation in revenue growth forecasts, leading to a new consensus fair value of €9.43. What's in the News Evotec lowered FY2025 revenue guidance to EUR 760–800 million (previously EUR 840–880 million) due to changes in revenue mix and higher-than-expected cost savings; technology licensing is expected to contribute more, while Shared R&D faces market challenges.
User avatar
新しいナラティブ • Apr 30

Pharmaceutical Collaborations And Cost Savings Will Drive Excellence

Strengthened partnerships with major pharma companies and a focus on biologics manufacturing are expected to boost Evotec's revenue and earnings.
分析記事 • Nov 10

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Evotec SE ( ETR:EVT ) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters...
分析記事 • Nov 05

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb

Those holding Evotec SE ( ETR:EVT ) shares would be relieved that the share price has rebounded 32% in the last thirty...
分析記事 • Aug 17

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Investors in Evotec SE ( ETR:EVT ) had a good week, as its shares rose 4.5% to close at €5.80 following the release of...
分析記事 • Aug 08

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

The Evotec SE ( ETR:EVT ) share price has fared very poorly over the last month, falling by a substantial 45%. The...
分析記事 • Aug 03

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Apr 10

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

You may think that with a price-to-sales (or "P/S") ratio of 3.1x Evotec SE ( ETR:EVT ) is a stock worth checking out...
分析記事 • Mar 05

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Jan 09

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

With a median price-to-sales (or "P/S") ratio of close to 3.9x in the Life Sciences industry in Germany, you could be...

業績と収益の成長予測

XTRA:EVT - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202889745311387
12/31/2027818-30-416710
12/31/2026738-125-143-88
3/31/2026745-194-5319N/A
12/31/2025788-104-92-9N/A
9/30/2025756-159-911N/A
6/30/2025777-15612112N/A
3/31/2025788-207-7635N/A
12/31/2024797-196-11418N/A
9/30/2024777-171-209-36N/A
6/30/2024788-171-246-55N/A
3/31/2024777-91-228-12N/A
12/31/2023781-84-18036N/A
9/30/2023821-95-188-14N/A
6/30/2023798-103-246-42N/A
3/31/2023800-116-39143N/A
12/31/2022751-17624206N/A
9/30/2022698-180121297N/A
6/30/20226842194322N/A
3/31/20226509058183N/A
12/31/20216182163122N/A
9/30/2021571247-5886N/A
6/30/2021541112-5093N/A
3/31/202151542-9920N/A
12/31/20205016-5445N/A
9/30/202048514-462N/A
6/30/202047035046N/A
3/31/2020462424382N/A
12/31/201944638N/A42N/A
9/30/201941961N/A29N/A
6/30/201940477N/A74N/A
3/31/201939894N/A139N/A
12/31/201837584N/A156N/A
9/30/201837063N/A135N/A
6/30/201833831N/A80N/A
3/31/201829420N/A19N/A
12/31/201726423N/A11N/A
9/30/201721528N/A64N/A
6/30/201719335N/A73N/A
3/31/201717836N/A74N/A
12/31/201616528N/A67N/A
9/30/201616018N/A5N/A
6/30/20161486N/A-6N/A
3/31/201614417N/A-2N/A
12/31/201512817N/A16N/A
9/30/201511912N/A19N/A
6/30/201510411N/A23N/A

アナリストによる今後の成長予測

収入対貯蓄率: EVTは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 1.9% ) よりも高い成長率であると考えられます。

収益対市場: EVT今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: EVT今後 3 年以内に収益を上げることが予想されます。

収益対市場: EVTの収益 ( 6.6% ) German市場 ( 6.8% ) よりも低い成長が予測されています。

高い収益成長: EVTの収益 ( 6.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EVTの 自己資本利益率 は、3年後には低くなると予測されています ( 7.3 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/25 05:50
終値2026/05/25 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Evotec SE 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23

アナリスト機関
Christian EhmannBerenberg
Michael RyskinBofA Global Research
Peter VerdultCitigroup Inc